Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,728 JPY | -1.29% | +1.96% | +1.26% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.16 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.26% | 2.4B | C+ | ||
+24.86% | 74.58B | C+ | ||
-2.78% | 23.95B | C+ | ||
+5.38% | 8.55B | C | ||
+10.64% | 8.52B | B | ||
-22.31% | 7.85B | B- | ||
+11.90% | 5.18B | B- | ||
+1.86% | 4.17B | B | ||
-5.04% | 4.06B | B- | ||
+3.71% | 3.89B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 9987 Stock
- Ratings Suzuken Co., Ltd.